The European Medicines Agency (EMA) has granted orphan drug status to OctreoPharm Sciences’ SOMscan, used for the diagnosis of gastro-entero-pancreatic neuroendocrine tumours.
The new Gallium-68-labeled radioactive contrast agent for PET has the potential to detect Phase I neuroendocrine tumours.
Go deeper with GlobalData
SOMscan binds to four out of five specific tumour receptor subtypes, which may allow detection of tumours that previously escaped discovery in imaging.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
